Roche Reports In Line Sales Figures -- Market Talk
Dow Jones04-23
0810 GMT - Roche's first-quarter sales are largely in line with expectations, Jefferies analysts write. The Swiss pharmaceutical company will host a call later Thursday which is likely to focus on its long-term sales outlook, they write. Roche's confidence in its multiple sclerosis drug fenebrutinib will also be scrutinized, they add. Market watchers will also be interested in the commercial opportunity for its giredestrant breast cancer drug, they say. Shares are up 2.3% to 320.4 Swiss francs. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
April 23, 2026 04:10 ET (08:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments